Gaboxadol

Gaboxadol

Systematic (IUPAC) name
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	64603-91-4 N
ATC code	None
PubChem	CID 3448
ChemSpider	3330 Y
UNII	K1M5RVL18S Y
KEGG	D04282 Y
ChEMBL	CHEMBL312443 Y
Chemical data
Formula	C6H8N2O2
Mol. mass	140.14 g/mol
SMILES O=C1/C2=C(\ON1)CNCC2
InChI InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) Y Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N Y
N (what is this?)  (verify)

Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way from benzodiazepines and Z-drugs (zolpidem, zaleplon, etc.).^{[citation needed]} Lundbeck states that gaboxadol also increases deep sleep (stage 4). Unlike benzodiazepines, it is not reinforcing.

See also

• Muscimol

External links

• 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol at the US National Library of Medicine Medical Subject Headings (MeSH)
• H. Lundbeck Website
• Medical News Today article
• Report of cancellation of development.